Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN- 207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 5, 1999, Pages 1095-1103

  Miyazaki, Masahiro ^b   Schally, Andrew V ^a   Nagy, Attila ^b   Lamharzi, Najib ^b   Halmos, Gabor ^b   Szepeshazi, Karoly ^b   Armatis, Patricia ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Cytotoxic luteinizing hormone releasing hormone analog; Epidermal growth factor; Nude mice; Ovarian cancer; Targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0345304646     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70600-9     Document Type: Article

References (26)

1. 1. Chemotherapy of gynecologic cancers. Rubin SC, editor. Philadelphia: Lippincott Raven; 1996. p. 91.
2. 2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. 3. Emons G, Schally AV. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancer. Hum Reprod 1994;9:1364-9.
4. 4. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JR, Frei E 3d, Bast RR Jr, Kufe DE, Morton DL, Weichselbaum RR, editors. Cancer medicine. 4th ed. Baltimore: Williams & Wilkins; 1997. p. 1067-86.
5. 6]luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489-98.
6. 6. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anticancer Drugs 1992;3:109-16.
7. 7. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, et al. LH-RH analogs with cytotoxic radicals. In: Treatment with Gn-RH analogs: controversies and perspectives. Filicori M, Flamigni C, editors. Carnforth (UK): Parthenon; 1996. p. 33-44.
8. 8. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A 1996;93:7269-73.
9. 9. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone - releasing hormone. J Natl Cancer Inst 1997;89:1803-9.
10. 10. Horowitz AT, Treves AJ, Voss R, Okon E, Fuks Z, Davidson L, et al. A new human ovarian carcinoma cell line: establisment and analysis of tumor associated markers. Oncology 1985;42:332-7.
11. 11. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, et al. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995;63:282-7.
12. 12. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A 1994;91:7090-4.
13. 13. Tomayko MM, Reynohls CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
14. 14. Szepeshazi K, Korkut E, Schally AV. Decrease in the AgNOR number in Dunning R-3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. Am J Pathol 1991;138:1273-7.
15. 15. Halmos G, Schally AV, Pinski J, Buenfil MV, Groot K. Down-regulation of pituary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci U S A 1996;93:2398-402.
16. 16. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonists RC-3095. Proc Natl Acad Sci U S A 1997;94:956-60.
17. 17. Munson PJ, Rodbard D. LIGAND, a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-39.
18. 18. Steel RG, Torrie J. Principle and procedures of statistics. New York; McGraw-Hill; 1976. p. 114.
19. 19. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991;254:1173-7.
20. 20. Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, et al. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy. J Natl Cancer Inst 1997;89:1217-23.
21. 21. Emons G, Ortmann O, Teichert HM, Fassi HG, Lohrs U, Kullander S, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: a prospective double blind randomized trial. Cancer 1996;78;1452-60.
22. 22. Arteaga CL, Hanauske AR, Clark GM, Osborne CK, Hazarika P, Pardue RL, et al. Immunoreactive a transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patients prognosis. Cancer Res 1988;48:5023-8.
23. 23. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: I, Correlation of receptor expression with prognosis faetors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-74.
24. 24. Morishige K, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A, et al. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991;51:5322-8.
25. 25. Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfleiderer A, et al. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas; classification of malignant phenotypes. Cancer 1993;71:419-29.
26. 26. Bartlett JM, Langdon SP, Simpson BJ, Katsaros D, Sismondi P, Love S, et al. The prognosis value of epidermal growth factor receptor m-RNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6.